FDA approves new experimental Alzheimer’s drug

By Abigail Adcox

Published January 6, 2023 7:16pm ET

Add Washington Examiner on Google

FDA approves new experimental Alzheimer’s drug — President Trump signed into law the FDA Reauthorization Act of 2017 on Friday. It reauthorizes a program in which drug and device makers pay the FDA a fee for every new product application, and the agency uses that money to hire more people and speed up approvals. (AP Photo/Andrew Harnik, File) | Andrew Harnik

The Food and Drug Administration granted accelerated approval for Eisai and Biogen’s experimental Alzheimer’s drug, lecanemab, on Friday, offering a new treatment option for the more than 6.5 million people with Alzheimer’s disease in the United States.

Print subscriber? Click here to login/register your account

Digital subscriber? Click here to login/register your account.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.

Tag:

Alzheimer's FDA Pharmaceutical Industry